InxMed Unveils Lfebemtinib for First-Line Non-Small Cell Lung Cancer (NSCLC) Treatment with KRAS G12C Mutation
InxMed has introduced Ifebemtinib for the first-line (1L) treatment of non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, in combination with garsorasib, a targeted inhibitor specifically designed for the KRAS G12C mutation.
Ifebemtinib is a highly selective, orally administered small-molecule inhibitor targeting focal adhesion kinase. It has demonstrated significant clinical synergies with targeted therapies, immunotherapies, and standard chemotherapies.
The Breakthrough Therapy Designation (BTD) for Ifebemtinib is supported by data from a Phase Ib/II study assessing its efficacy and safety in combination with garsorasib for 1L treatment of KRAS G12C-mutated NSCLC.
The dual-oral regimen showcased significant antitumor activity with a strong safety profile, recording an objective response rate (ORR) of 90.3 percent and a disease control rate (DCR) of 96.8 perccent. Out of 31 evaluable patients, 28 experienced confirmed partial responses (PRs), and two achieved stable disease (SD).
Moreover, Ifebemtinib has demonstrated remarkable therapeutic synergies when combined with a variety of established and emerging cancer treatments, including anti-PD-(L)1 antibodies, other RAS-targeted inhibitors, EGFR inhibitors, and antibody-drug conjugates (ADCs).
